These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

460 related items for PubMed ID: 37309038

  • 41.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 42. No impact of hyperkalaemia with renin-angiotensin system blockades in maintenance haemodialysis patients.
    Han SW, Won YW, Yi JH, Kim HJ.
    Nephrol Dial Transplant; 2007 Apr; 22(4):1150-5. PubMed ID: 17255126
    [Abstract] [Full Text] [Related]

  • 43. Comparative efficacy of seven Chinese patent medicines for early diabetic kidney disease: A Bayesian network meta-analysis.
    Zhao J, Ai J, Mo C, Shi W, Meng L.
    Complement Ther Med; 2022 Aug; 67():102831. PubMed ID: 35398481
    [Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47. Effect of pre-transplantation use of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker in kidney transplant recipients-propensity score-matched analysis.
    Lee J, Jung CY, Kim H, Kim HJ, Ko Y, Kwon H, Shin S, Kim YH, Park SK, Baek CH.
    J Nephrol; 2024 Jul; 37(6):1589-1597. PubMed ID: 38684638
    [Abstract] [Full Text] [Related]

  • 48. Risk factors associated with biochemically detected and hospitalised acute kidney injury in patients prescribed renin angiotensin system inhibitors.
    Mark PB, Papworth R, Ramparsad N, Tomlinson LA, Sawhney S, Black C, McConnachie A, McCowan C.
    Br J Clin Pharmacol; 2020 Jan; 86(1):121-131. PubMed ID: 31663151
    [Abstract] [Full Text] [Related]

  • 49. Renoprotective effect of renin-angiotensin-aldosterone system blockade in patients with predialysis advanced chronic kidney disease, hypertension, and anemia.
    Hsu TW, Liu JS, Hung SC, Kuo KL, Chang YK, Chen YC, Hsu CC, Tarng DC.
    JAMA Intern Med; 2014 Mar; 174(3):347-54. PubMed ID: 24343093
    [Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51. Adverse effects during treatment with renin-angiotensin-aldosterone system inhibitors; should we stay or should we stop?
    Leon SJ, Carrero JJ.
    Curr Opin Nephrol Hypertens; 2023 May 01; 32(3):290-296. PubMed ID: 36811640
    [Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53. What are the risks and benefits of temporarily discontinuing medications to prevent acute kidney injury? A systematic review and meta-analysis.
    Whiting P, Morden A, Tomlinson LA, Caskey F, Blakeman T, Tomson C, Stone T, Richards A, Savović J, Horwood J.
    BMJ Open; 2017 Apr 07; 7(4):e012674. PubMed ID: 28389482
    [Abstract] [Full Text] [Related]

  • 54. Low body mass index is a risk factor for hyperkalaemia associated with angiotensin converting enzyme inhibitors and angiotensin II receptor blockers treatments.
    Hirai T, Yamaga R, Fujita A, Itoh T.
    J Clin Pharm Ther; 2018 Dec 07; 43(6):829-835. PubMed ID: 29908131
    [Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 23.